CD200 and breast cancer: Our data suggest that optimal treatment of breast cancer should take into consideration the importance in "trade-off" between cancer cell sterilization by immunosuppressive drug treatment and the potential benefit of enhancing immune resistance by manipulation of co-inhibitory (CD200) pathways.